{"id":"erismodegib","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT02151864","NCT02303041","NCT04007744","NCT01694589","NCT06880848","NCT02086513","NCT02195973","NCT03070691","NCT01350115","NCT01769768","NCT02182622","NCT02111187","NCT01529450","NCT04806646","NCT02358161","NCT01757327","NCT05463757","NCT01033019","NCT05669339","NCT03434262","NCT01208831","NCT01911416","NCT01485744","NCT01954355","NCT02027376","NCT01579929","NCT02254551","NCT01708174","NCT00880308","NCT05561634","NCT02002689","NCT01576666","NCT01764776","NCT00961896","NCT01787552","NCT06623201","NCT01456676","NCT01125800","NCT04679480","NCT01327053","NCT01487785","NCT01431794","NCT04402073","NCT02086552","NCT07068568","NCT01826214","NCT02138929","NCT03534947","NCT04066504","NCT02129101"],"aliases":["Smoothened antagonist LDE225","Sonidegib"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Erismodegib","companyId":"washington-university-school-of-medicine","ecosystem":[],"mechanism":{"target":"Smoothened homolog, Sonic hedgehog protein","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Washington University School of Medicine","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Erismodegib","indications":{"approved":[{"name":"Basal cell carcinoma of skin","diseaseId":"basal-cell-carcinoma-of-skin","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02151864","phase":"Phase 1","title":"Phase Ib Study of Single Agent LDE225, an Oral Hedgehog Inhibitor, as Second-Line Therapy in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis","status":"COMPLETED","sponsor":"Jason K. Sicklick, M.D.","isPivotal":false,"enrollment":9,"indication":"Hepatocellular Carcinoma, Cirrhosis","completionDate":"2017-09"},{"nctId":"NCT02303041","phase":"Phase 2","title":"An Open-Label Pilot Study to Evaluate the Efficacy and Safety of a Combination Treatment of Sonidegib (LDE225) and Buparlisib (BKM120) For the Treatment of Advanced Basal Cell Carcinomas","status":"TERMINATED","sponsor":"Anne Chang","isPivotal":false,"enrollment":10,"indication":"Carcinoma, Basal Cell, Recurrent Skin Cancer","completionDate":"2017-06"},{"nctId":"NCT04007744","phase":"Phase 1","title":"Phase I Trial of Sonidegib and Pembrolizumab in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":36,"indication":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8","completionDate":"2027-07-02"},{"nctId":"NCT01694589","phase":"EARLY/Phase 1","title":"A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer","status":"WITHDRAWN","sponsor":"Rutgers, The State University of New Jersey","isPivotal":false,"enrollment":0,"indication":"Resectable Pancreatic Cancer","completionDate":"2014-07"},{"nctId":"NCT06880848","phase":"Phase 4","title":"A Prospective, Open-Label, Single-Arm, Multi-Center, Phase IV Efficacy and Safety Study of Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China","status":"COMPLETED","sponsor":"Jemincare","isPivotal":false,"enrollment":160,"indication":"Carcinoma, Basal Cell (BCC)","completionDate":"2025-08-26"},{"nctId":"NCT02086513","phase":"Phase 1","title":"Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT","status":"TERMINATED","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":17,"indication":"Graft Versus Host Disease","completionDate":"2016-12"},{"nctId":"NCT02195973","phase":"Phase 1","title":"Phase IB Trial of LDE225 and Weekly Paclitaxel in Recurrent Platinum Resistant Ovarian Cancer","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","isPivotal":false,"enrollment":15,"indication":"Recurrent Ovarian Cancer","completionDate":"2017-09-30"},{"nctId":"NCT03070691","phase":"Phase 2","title":"A Randomized, Double-blind, Vehicle-controlled, Multicenter Trial of Topically Administered LDE225 Cream (0.75% Bid) to Evaluate Clearance of Basal Cell Carcinoma in Adult Patients With Nevoid Basal C","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","isPivotal":true,"enrollment":0,"indication":"Basal Cell Carcinoma","completionDate":""},{"nctId":"NCT01350115","phase":"Phase 2","title":"A Phase II, Double-blind, Randomized, Proof-of-Concept, Dose-ranging Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Adult Patients With Nevoid Basal Cell Car","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":10,"indication":"Basal Cell Carcinoma, Gorlin Syndrome","completionDate":"2012-10"},{"nctId":"NCT01769768","phase":"Phase 1","title":"A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid T","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":114,"indication":"Advanced Solid Tumor","completionDate":"2016-08"},{"nctId":"NCT02182622","phase":"Phase 1","title":"Ib Dose Finding Study of LDE225 Plus Docetaxel/Prednisone in Patients With Advanced or Metastatic Castration Resistant Prostate Cancer Who Experience Disease Progression After Receiving Docetaxel","status":"WITHDRAWN","sponsor":"Martin Gutierrez","isPivotal":false,"enrollment":0,"indication":"Prostate Cancer","completionDate":"2015-12"},{"nctId":"NCT02111187","phase":"Phase 1","title":"A Pharmacodynamic Pre-surgical Study of Hedgehog Pathway Inhibition With LDE225 in Men With High-risk Localized Prostate Cancer.","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","isPivotal":false,"enrollment":14,"indication":"Prostate Cancer","completionDate":"2017-01-18"},{"nctId":"NCT01529450","phase":"NA","title":"A Pilot Open-Label Study to Examine the Safety and Efficacy of Oral LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Who Have Been Previously Treated With Non-LDE225 Smoothe","status":"COMPLETED","sponsor":"Anne Chang","isPivotal":false,"enrollment":11,"indication":"Basal Cell Carcinoma","completionDate":"2013-08"},{"nctId":"NCT04806646","phase":"Phase 2","title":"A Phase II, Open-label Study Improving Compliance and Time of Treatment After Obtaining Complete Response Through a Tailored Schedule of Sonidegib in Locally Advanced Basal Cell Carcinomas (BCC) - the","status":"UNKNOWN","sponsor":"Gruppo Oncologico del Nord-Ovest","isPivotal":false,"enrollment":21,"indication":"Locally Advanced Basal Cell Carcinoma","completionDate":"2026-01-12"},{"nctId":"NCT02358161","phase":"Phase 1","title":"Phase I/II Study of LDE225 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Locally Advanced or Metastasized Pancreatic Cancer","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","isPivotal":false,"enrollment":78,"indication":"Pancreatic Cancer","completionDate":"2019-01"},{"nctId":"NCT01757327","phase":"Phase 2","title":"A Randomized Placebo-Controlled Phase II Trial Evaluating the Effect of Hedgehog Inhibitor LDE225 on Bone Marrow Disseminated Tumor Cells in Women With Early Stage Estrogen Receptor Negative and HER2 ","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":0,"indication":"Breast Neoplasms","completionDate":"2019-12"},{"nctId":"NCT05463757","phase":"N/A","title":"Registration of Oral Hedgehog Inhibitors Vismodegib and Sonidegib in the Treatment of Advanced and Multiple Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study.","status":"RECRUITING","sponsor":"Maastricht University Medical Center","isPivotal":false,"enrollment":80,"indication":"Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma","completionDate":"2026-12"},{"nctId":"NCT01033019","phase":"Phase 2","title":"Double-blind, Randomized, Vehicle-controlled Proof of Concept Study on the Efficacy, Safety, Local Tolerability, PK and Pharmacodynamics of Multiple Topical Administrations of LDE225 on Sporadic Super","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":25,"indication":"Sporadic Superficial and Nodular Skin Basal Cell Carcinomas","completionDate":"2011-02"},{"nctId":"NCT05669339","phase":"Phase 2","title":"AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"University of Florida","isPivotal":false,"enrollment":12,"indication":"Hepatocellular Carcinoma","completionDate":"2026-04"},{"nctId":"NCT03434262","phase":"Phase 1","title":"Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","isPivotal":false,"enrollment":68,"indication":"Anaplastic Astrocytoma, Anaplastic Ependymoma","completionDate":"2024-05-24"},{"nctId":"NCT01208831","phase":"Phase 1","title":"An East Asian Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":45,"indication":"Advanced Solid Tumor Cancers, Medulloblastoma","completionDate":"2013-10"},{"nctId":"NCT01911416","phase":"NA","title":"A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer","status":"WITHDRAWN","sponsor":"University of Utah","isPivotal":false,"enrollment":0,"indication":"Pancreatic Ductal Adenocarcinoma","completionDate":"2014-10"},{"nctId":"NCT01485744","phase":"Phase 1","title":"A Phase 1b Clinical Trial of LDE225 in Combination With Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX) in Previously Untreated Locally Advanced or Metastatic Pancreatic Adenocarcino","status":"COMPLETED","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":39,"indication":"Pancreatic Cancer","completionDate":"2019-11"},{"nctId":"NCT01954355","phase":"Phase 1","title":"LDE225 in Combination With Paclitaxel in Patients With Advanced Solid Tumors - A Multicenter Phase I Trial","status":"COMPLETED","sponsor":"Swiss Cancer Institute","isPivotal":false,"enrollment":30,"indication":"Solid Tumor, Ovarian Cancer","completionDate":"2016-11"},{"nctId":"NCT02027376","phase":"Phase 1","title":"A Phase Ib Dose Escalation, Open Label, Multicenter Study Evaluating LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients \"EDALINE\"","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","isPivotal":false,"enrollment":12,"indication":"Advanced Breast Cancer","completionDate":"2016-04"},{"nctId":"NCT01579929","phase":"Phase 1","title":"A Phase I Trial of the Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":19,"indication":"Lung Cancer","completionDate":"2017-08-11"},{"nctId":"NCT02254551","phase":"Phase 2","title":"Phase II Trial of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With a Dose-Finding Lead-In","status":"TERMINATED","sponsor":"SCRI Development Innovations, LLC","isPivotal":false,"enrollment":7,"indication":"Multiple Myeloma","completionDate":"2015-10"},{"nctId":"NCT01708174","phase":"Phase 2","title":"A Phase II, Multi-center, Open-label, Single-arm Study of the Efficacy and Safety of Oral LDE225 in Patients With Hh-pathway Activated Relapsed Medulloblastoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":22,"indication":"Medulloblastoma","completionDate":"2016-10-05"},{"nctId":"NCT00880308","phase":"Phase 1","title":"A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":103,"indication":"Advanced Solid Tumor Cancers, Medulloblastoma","completionDate":"2013-07"},{"nctId":"NCT05561634","phase":"Phase 2","title":"Evaluation of Radiotherapy After Complete Response to Sonic Hedgehog Pathway Inhibitors in Patients With Locally Advanced Basal Cell Carcinoma: a Prospective Multicenter Study","status":"RECRUITING","sponsor":"University Hospital, Lille","isPivotal":false,"enrollment":82,"indication":"Basal Cell Carcinoma, Radiotherapy; Complications","completionDate":"2029-06-20"},{"nctId":"NCT02002689","phase":"Phase 2","title":"Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 5 LDE225 for Patients With PTCH1 or SMO Mutated Tumors","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":10,"indication":"PTCH1 or SMO Activated Solid and Hematologic Tumors","completionDate":"2015-03"},{"nctId":"NCT01576666","phase":"Phase 1","title":"A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":120,"indication":"Dose Escalation, Safety","completionDate":"2015-04"},{"nctId":"NCT01764776","phase":"Phase 1","title":"A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDE225 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":33,"indication":"Normal Hepatic Function, Impaired Hepatic Function","completionDate":"2015-03"},{"nctId":"NCT00961896","phase":"Phase 2","title":"A Double-blind, Randomized, Vehicle-controlled Proof of Concept (PoC) Study to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Topical Administrations of LDE","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":18,"indication":"Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients","completionDate":""},{"nctId":"NCT01787552","phase":"Phase 1","title":"A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":50,"indication":"Primary Myelofibrosis, Thrombocytosis","completionDate":"2018-04-10"},{"nctId":"NCT06623201","phase":"Phase 1","title":"Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas","status":"RECRUITING","sponsor":"Nathalie Zeitouni","isPivotal":false,"enrollment":20,"indication":"Basal Cell Carcinoma (BCC)","completionDate":"2026-12-01"},{"nctId":"NCT01456676","phase":"Phase 1","title":"A Single-arm Dose-finding Phase Ib Multicenter Study of the Oral Smoothened Antagonist LDE225 in Combination With Nilotinib in Chronic or Accelerated Phase of Chronic Myeloid Leukemia Patients Who Hav","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":11,"indication":"Philadelphia Chromosome Positive Chronic Myelogenous Leukemia","completionDate":"2014-02"},{"nctId":"NCT01125800","phase":"Phase 1","title":"A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurren","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":76,"indication":"Medulloblastoma, Rhabdomyosarcoma","completionDate":"2014-10"},{"nctId":"NCT04679480","phase":"Phase 2","title":"A Prospective, Open, Single-arm, Single Center, Phase II Trial to Assess the Efficacy of Anti-PD1 Antibody in Combination With Pulsed Hedgehog Inhibitor in Advanced Basal Cell Carcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Reinhard Dummer","isPivotal":false,"enrollment":20,"indication":"Basal Cell Carcinoma","completionDate":"2024-12-30"},{"nctId":"NCT01327053","phase":"Phase 2","title":"Phase II, Randomized Double-blind Study of Efficacy and Safety of Two Dose Levels of LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":230,"indication":"Basal Cell Carcinoma","completionDate":"2018-06-29"},{"nctId":"NCT01487785","phase":"Phase 1","title":"A Phase Ib, Open-label, Multicenter, Dose-escalation, Safety and Tolerability Study of LDE225 in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":18,"indication":"Pancreatic Cancer","completionDate":"2014-07"},{"nctId":"NCT01431794","phase":"Phase 1","title":"Phase 1/2 Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma.","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","isPivotal":false,"enrollment":23,"indication":"Pancreatic Ductal Adenocarcinoma","completionDate":"2018-11-05"},{"nctId":"NCT04402073","phase":"Phase 2","title":"Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I)","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","isPivotal":false,"enrollment":20,"indication":"Medulloblastoma","completionDate":"2025-09-10"},{"nctId":"NCT02086552","phase":"Phase 2","title":"Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":28,"indication":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","completionDate":"2021-08-13"},{"nctId":"NCT07068568","phase":"N/A","title":"Dose Modulation Strategy of Sonidegib for Eye-Sparing Treatment of Locally Advanced Periocular Basal Cell Carcinoma","status":"COMPLETED","sponsor":"Federico II University","isPivotal":false,"enrollment":12,"indication":"Basal Cell Cancer, Eyelid Tumor","completionDate":"2024-03-20"},{"nctId":"NCT01826214","phase":"Phase 2","title":"A Phase II Multi-center, Open Label, Randomized Study to Assess Safety and Efficacy of Two Different Schedules of Oral LDE225 in Adult Patients With Relapsed/Refractory or Untreated Elderly Patients W","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":70,"indication":"Acute Leukemias","completionDate":"2015-05"},{"nctId":"NCT02138929","phase":"Phase 1","title":"A Phase I Study of LDE225 in Combination With Everolimus in Patients With Advanced Gastroesophageal Adenocarcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":25,"indication":"Esophageal Cancer","completionDate":"2020-06-08"},{"nctId":"NCT03534947","phase":"Phase 2","title":"A Pilot Study to Evaluate Short Term Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinomas in Cosmetically Challenging Locations","status":"COMPLETED","sponsor":"Melanoma Institute Australia","isPivotal":false,"enrollment":16,"indication":"Basal Cell Carcinoma, Basal Cell Carcinoma of Skin, Site Unspecified","completionDate":"2025-03-01"},{"nctId":"NCT04066504","phase":"N/A","title":"A Non-interventional, Multi-national, Multi-center Post-authorization Safety Study (PASS) to Assess the Long Term Safety and Tolerability of Odomzo (Sonidegib) Administered in Patients With Locally Ad","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","isPivotal":false,"enrollment":323,"indication":"Basal Cell Carcinoma","completionDate":"2025-03-14"},{"nctId":"NCT02129101","phase":"Phase 1","title":"Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies","status":"COMPLETED","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":63,"indication":"Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome","completionDate":"2019-10-25"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}